Literature DB >> 16790847

Current status of clinical islet cell transplantation.

Jonathan R T Lakey1, Mohammadreza Mirbolooki, A M James Shapiro.   

Abstract

Clinical outcomes of pancreas transplantation were superior to that of islet transplantation until the introduction of the Edmonton protocol. Significant advances in islet isolation and purification technology, novel immunosuppression and tolerance strategies, and effective antiviral prophylaxis have renewed interest in clinical islet transplantation for the treatment of diabetes mellitus. The introduction of a steroid-free antirejection protocol and islets prepared from two donors led to high rates of insulin independence. The Edmonton protocol has been successfully replicated by other centers in an international multicenter trial. A number of key refinements in pancreas transportation, islet preparation, and newer immunological conditioning and induction therapies have led to continued advancement through extensive collaboration between key centers. This chapter provides an overview of the history of islet transplantation followed by a discussion of the state of the art of clinical islet transplantation. The challenges facing the clinician-scientist in the 21st century are also presented in this review.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790847     DOI: 10.1385/1-59745-049-9:47

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  PEG-maleimide hydrogels for protein and cell delivery in regenerative medicine.

Authors:  Andrés J García
Journal:  Ann Biomed Eng       Date:  2013-07-24       Impact factor: 3.934

2.  Identification and characterization of a novel expandable adult stem/progenitor cell population in the human exocrine pancreas.

Authors:  M A Puglisi; L Giuliani; A Fierabracci
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 3.  Stem cell therapy for type 1 diabetes mellitus.

Authors:  Cristina Aguayo-Mazzucato; Susan Bonner-Weir
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

Review 4.  Vaccination against type 1 diabetes.

Authors:  H E Larsson; Å Lernmark
Journal:  J Intern Med       Date:  2011-06       Impact factor: 8.989

5.  Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization.

Authors:  Edward A Phelps; Kellie L Templeman; Peter M Thulé; Andrés J García
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

6.  Impact of islet transplantation on diabetes complications and quality of life.

Authors:  Roberto Bassi; Paolo Fiorina
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

7.  Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts.

Authors:  Yang-Hee Kim; Yu-Mee Wee; Monica-Y Choi; Dong-Gyun Lim; Song-Cheol Kim; Duck-Jong Han
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

8.  Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes.

Authors:  Edward A Phelps; Devon M Headen; W Robert Taylor; Peter M Thulé; Andrés J García
Journal:  Biomaterials       Date:  2013-03-26       Impact factor: 12.479

9.  Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells.

Authors:  Zaida Alipio; Wenbin Liao; Elizabeth J Roemer; Milton Waner; Louis M Fink; David C Ward; Yupo Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-07       Impact factor: 11.205

Review 10.  Pancreas regeneration.

Authors:  Qiao Zhou; Douglas A Melton
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.